Study tests tumor testing to predict nodal marginal zone lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects and analyzes tumor samples from people with nodal marginal zone lymphoma to better understand the disease and predict outcomes. It may help doctors characterize the lymphoma more accurately using clinical and lab information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You were diagnosed with nodal marginal zone lymphoma based on lymph node biopsy (tissue study).
- Your diagnosis needs to be after January 1, 2000.
- You have usable tumor tissue saved from before treatment (either frozen or preserved FFPE tissue).
- Your records include baseline information and follow-up information about your illness.
- Your doctors have checked that there is no hidden spread to nearby organs/tissues (extranodal disease) draining to the involved lymph node, using imaging and/or endoscopy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
This trial compares three treatment combinations for marginal zone lymphoma (a slow-growing blood cancer) that has come back or not improved after earlier treatment. It tests a new drug alone or with another drug to see which approach works better.
This study looks at tissue samples from people who have a more aggressive form of splenic marginal zone lymphoma. It aims to better understand the genetic changes that happen when the disease transforms, which may help doctors predict and treat this condition in the future.
This trial studies tissue samples from people with MALT lymphoma (a type of low-grade lymphoma) to learn more about its biology. It aims to improve understanding of the disease, which could help future treatments.
Hear when a new Nodal Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.